Prostate specific membrane antigen, a unique glutamate carboxypeptidase: A review of recent findings

Prostate Journal

Volumn 1, Issue 1, 1999, Pages 15-26

  Pinto, John Thomas ^a   Heston, Warren D W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002823795     PISSN: 10955100     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Horoszewicz JS, Kawinski E, Murphy GP. (1987) Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res. 7: 927-936.
2. Horoszewicz JS, Leong SS, Kawinski E, et al. (1983) LNCaP model of human prostatic carcinoma. Cancer Res. 43: 1809-1818.
3. Wright GL Jr., Haley C, Beckett ML, Schellhammer PF. (1995) Expression of prostate specific membrane antigen (PSMA) in normal, benign, and malignant prostate tissues. Urol. Oncol. 1: 18-28.
4. Lopes AD, Davis WL, Rosenstranus MJ, Uveges AJ, Gilman S. (1990) Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res. 50: 6423-6428.
5. Troyer JK, Beckett ML, Wright GL Jr. (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J. Cancer 62: 552-558.
6. Liu H, Moy P, Kim S, et al. (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57: 3629-3634.
7. Israeli RS, Miller WH Jr., Su SL, et al. (1994) Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate specific antigen-based assays. Cancer Res. 54: 6306-6310.
8. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3: 81-85.
9. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. (1994) Expression of the prostate-specific membrane antigen. Cancer Res. 54: 1807-1811.
10. Israeli RS, Miller WH Jr., Su SL, et al. (1995) Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J. Urol. 153: 573-577.
11. Vessella R, Stray J, Arfman E, Ellis W, Lange R. (1994) Reverse transcription polymerase chain reaction (RT-PCR) detects metastatic prostate cancer cells in lymph nodes, blood, and potentially bone marrow using PSA mRNA as template. J. Urol. 151(Suppl 5): 412. Abstract.
12. Deguchi T, Doi T, Ehara H, et al. (1993) Detection of micrometastatic prostate cancer cells in lymph nodes by reverse-transcriptase polymerase chain reaction. Cancer Res. 53: 5350-5354.
13. Katz AE, Olsson CA, Raffo AJ, et al. (1994) Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43: 765-775.
14. Loric S, Dumas F, Eschwege P, et al. (1995) Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma using nested RT-PCR assay based on prostate specific membrane antigen. Clin. Chem. 41: 1698-1704.
15. Kaplinsky RS, Su SL, Heston WDW, Miller WH, Fair WR. (1997) Neoadjuvant hormonal therapy reduces the incidence of circulating prostate cells as detected by RT-PCR. Mol. Urol. 1: 177-181.
16. Heston WDW. (1995) Detection of hematogenous dissemination of prostate cancer by RT-PCR with primers specific for prostate specific membrane antigen. Clin. Chem. 41: 1687-1688.
17. Ghossein R, Scher H, Gerald W, et al. (1994) Detection of circulating tumor cells in peripheral blood of patients with advanced prostatic carcinoma. Proc. Am. Soc. Clin. Oncol. 13: 237.
18. Israeli RS, Powell CT, Fair WR, Heston WDW. (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53: 227-230.
19. Wright GL Jr., Grob BM, Haley C, et al. (1996) Upregulation of prostate specific membrane antigen after androgen deprivation therapy. Urology 48: 326-334.
20. Kawakrami M, Nakayami J. (1997) Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 57: 2321-2324.
21. Uria JA, Velasco G, Santamaria I, Ferrando A, Lopez-Otin C. (1997) Prostate-specific membrane antigen in breast carcinoma. Lancet 349: 1601-1602.
22. Su SL, Huang I-P, Fair WR, Powell CT, Heston WDW. (1995) Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res. 55: 1441-1443.
23. Rinker-Schaeffer CW, Hawkins AL, Su SL, et al. (1995) Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics 30: 105-108.
24. Leek J, Lench N, Maraj B, et al. (1995) Prostate-specific membrane antigen: Evidence for the existence of a second related human gene. Br. J. Cancer 72: 583-588.
25. Maraj BH, Leek JP, Karayi M, Ali M, Lench NJ, Markham AF. (1998) Detailed genetic mapping around a putative prostate-specific membrane antigen locus on human chromosome 11p11.2. Cytogenet. Cell Genet. 81: 3-9.
26. O'Keefe DS, Su SL, Bacich DJ, et al. (1998) Mapping, genomic organization and promoter analysis of the human prostate specific membrane antigen gene. Biochem. Biophys. Acta. 1443: 113-127.
27. Pinto JT, Suffoletto BP, Berzin TM, et al. (1996) Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res. 2: 1445-1451.
28. Chandler CJ, Wang TTY, Halsted CH. (1986) Pteroylpolyglutamate hydrolase from human jejunal brush borders. Purification and characterization. J. Biol. Chem. 261: 928-933.
29. Holm J, Hansen SI, Hoier-Madsen M. (1993). High-affinity folate binding in human prostate. Biosci. Reports 13: 99-105.
30. Halsted CH, Ling EH, Luthi-Carter R, Villanueva JA, Gardner JM, Coyle JT. (1998) Folylpoly-γ glutamate carboxypeptidase from pig jejunum. Molecular characteriza-tion and relation to glutamate carboxypeptidase II. J Biol. Chem. 273: 20417-20424.
31. Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. Enzyme Nomenclature Recommendations 1992. Supplement 4 Corrections and Additions (1997). Eur. J. Biochem. 250: 1-6.
32. Heston WDW. (1997) Biologic implications of prostate function following identification of prostate-specific membrane antigen as a novel folate hydrolase/neurocarboxypeptidase. In: Naz RK (ed). Prostate: Basic and Clinical Aspects. Boca Raton, FL, CRC Press, pp. 267-298.
33. Heston WDW, Tong WP, Pinto JT. (1997) Prostate specific membrane antigen, a unique folate hydrolase: Potential target for prodrug therapy. Mol. Urol. 1: 215-219.
34. Carter RE, Feldman AR, Coyle JT. (1996) Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA. 93: 749-753.
35. Slusher BS, Robinson MB, Tsai G, Simmons ML, Richards SS, Coyle JT. (1990) Rat brain linked N-acetylated-α-linked acidic dipeptidase activity. Purification and immunologic characterization. J. Biol. Chem. 265: 21297-21301.
36. Luthi-Carter R, Barczak AK, Speno H, Coyle JT. (1998) Molecular characterization of human brain N-acetylated α-linked acidic dipeptidase (NAALADase). J. Pharmacol. Exp Ther. 286: 1020-1025.
37. Rawlings ND, Barrett AJ. (1997) Structure of membrane glutamate carboxypeptidase. Biochem. Biophys Acta 1339: 247-252.
38. Liu H, Rajasekaran AK, Moy P, et al. (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 58: 4055-4060.
39. Siess MH, Le Bon AM, Canivenc-Lavier MC, Suschetet M. (1997). Modification of hepatic drug-metabolizing enzymes in rats treated with alkyl sulfides. Cancer Lett. 120: 195-201.
40. Sepkovic DW, Qiao C, Pinto J, Bradlow HL. (1996) Phase II metabolism of various estrogens after treatment with aged garlic extract. Presented at the Annual Meeting of American Association for Cancer Research, Washington, DC, April 20-24.
41. Pinto JT, Qiao CH, Xing J, et al. (1997) Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. Am. J. Clin. Nutr. 66: 398-405.
42. Pinto JT, Qiao CH, Xing J, Suffoletto BP, Rivlin RS, Heston WDW. (1997) Garlic constituents modify expression of biomarkers for human prostatic carcinoma cells. FASEB J. 11: 439. Abstract.
43. Pinto JT, Qiao CH, Xing J, et al. (submitted) Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine.
44. 111indium-labelled monoclonal antibody, CYT-356. J. Urol. 52: 1952-1955.
45. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J. Urol. 152: 1490-1495.
46. 111In-labelled monoclonal antibody 7E11-C5.3 (Cyt 356). Prostate 18: 220-241.
47. Kahn D, Williams RD, Haseman MK, Miller SJ, Gerstbrein J. (1998) Radioimmunoscintigraphy with In-111 labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J. Clin Oncol. 16: 284-289.
48. Scher H, Sternberg CN. (1985) Chemotherapy of urologic malignancies. Semin. Urol. 3: 329-381.
49. Abdel-Nabi H, Wright GL, Gulfo JV, et al. (1992) Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin. Urol. 10: 45-54.
50. Barren RJ III, Holmes EH, Boynton AL, Misrock SL, Murphy GP. (1997) Monoclonal antibody 7E11-C5 staining of viable LNCaP cells. Prostate 30: 65-68.
51. Graurer LS, Pusateri KD, Margnac J, Wolfert RL. (1998) Identification of PSM protein in cytoplasm of the prostate carcinoma cell line, LNCaP. Proc. Am Assoc. Cancer Res. 39(Abstract 3767): 554.
52. Woynarowska B, Robinson SC, Woynarowski JM, Roberts K. (1997) The inhibition of tumor cell growth by antisense oligo-nucleotide targeted against prostate-specific membrane antigen. Proc. Am. Assoc. Cancer Res. 38(Abstract 2112): 315.
53. Jackson PF, Slusher BS. (1997) Certain phosphonomethylpentanedioic acid derivatives thereof. US Patent #5,672,592.
54. Lowe KE, Osborne CB, Lin B-F, Kim J-S, Hsu J-C, Shane B. (1993) Regulation of folate and one-carbon metabolism in mammalian cells. II. Effect of folylpoly-γ-glutamate synthetase substrate specificity and level on folate metabolism and folylpoly-γ-glutamate specificity of metabolic cycles on one-carbon . metabolism. J. Biol. Chem. 268: 21665-21673.
55. Heston WDW, Latouch J-B, Sadelain M, et al. (in press) Activation of an anticancer prodrug by the folate hydrolase activity of prostate-specific membrane antigen (PSMA): A potential therapeutic approach.
56. Banerjee D, Ercikan-Abali E, Waltham M, et al. (1995) Molecular mechanisms of resistance to antifolates, a review. Acta Biochim. Pol. 42: 457-464.
57. Rhee MS, Wang Y, Nair MG, Galivan J. (1993) Acquisition of resistance of antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res. 53: 2227-2230.
58. Li WW, Waltham M, Tong W, Schweitzer BI, Bertino JR. (1993) Increased activity of γ-glutamyl hydrolase in human sarcoma cell lines: A novel mechanism of intrinsic resistance to methotrexate (MTX). Adv. Exp. Med. Biol. 338: 635-638.
59. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE. (1993) Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71: 3952-3965.
60. Yatani R, Kusano I, Shiraishi T, Hayashi T, Stemmermann GN. (1989) Latent prostatic carcinoma: pathological and epidemiological aspects. Jpn. J. Clin. Oncol. 19: 319-326.
61. 213Bi-J591 (anti-PSMA) treatment of LNCaP spheroids. Proc. Am. Assoc. Cancer Res. 39(Abstract 2996): 440.
62. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. (1998) Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. 4: 295-302.